Succimer: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antidote *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: ==Adult Dosing== *Lead poisoning: 10 to 30 mg/kg/day for 5 da...") |
(Links. Information of pharmacology) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antidote]] | *Type: [[Antidote]] | ||
*Dosage Forms: | *Dosage Forms: Capsule 100mg | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: | *Common Trade Names: Chemet | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Lead poisoning]]=== | |||
*10 to 30 mg/kg/day for 5 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established in patients <12mo'' | ''Safety/efficacy not established in patients <12mo'' | ||
| Line 18: | Line 19: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Breastfeeding during treatment and five days after d/c | |||
*ANC < 1200 | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Neutropenia | *[[Neutropenia]] | ||
*[[Arrhythmia]] | |||
===Common=== | ===Common=== | ||
*Rash | *Rash | ||
*Nausea/vomiting, diarrhea, decreased appetite | *[[Nausea]]/[[vomiting]], [[diarrhea]], decreased appetite | ||
*Elevated transaminases | *Elevated transaminases | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 48h | *Half-life: 48h | ||
*Metabolism: | *Metabolism: Site unknown | ||
*Excretion: Renal 25% | *Excretion: Renal 25%, feces 39%, lungs 1% | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 21:34, 8 September 2018
Administration
- Type: Antidote
- Dosage Forms: Capsule 100mg
- Routes of Administration: Oral
- Common Trade Names: Chemet
Adult Dosing
Lead poisoning
- 10 to 30 mg/kg/day for 5 days
Pediatric Dosing
Safety/efficacy not established in patients <12mo
- Lead poisoning, level >45 mcg/dL: 10 mg/kg or 350 mg/m(2) q8h for 5 days, then q12 h for 14 days
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: administer with caution, ensure adequate hydration
- Hepatic dosing: no adjustment, monitor LFTs closely
Contraindications
- Allergy to class/drug
- Breastfeeding during treatment and five days after d/c
- ANC < 1200
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 48h
- Metabolism: Site unknown
- Excretion: Renal 25%, feces 39%, lungs 1%
Mechanism of Action
- Forms stable, water-soluble complexes with lead, leading to increased urinary excretion